Clinical Trial Update: CESAR Study in Prostate Cancer With Temsirolimus Added to Standard Docetaxel Therapy (CEPTAS) [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 clinical trial (CEPTAS) evaluating the addition of temsirolimus to standard docetaxel therapy for prostate cancer has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prostate Cancer

Drugs mentioned

• Taxotere (docetaxel)
• Torisel (Temsirolimus)

Snippet

Sponsor: Central European Society for Anticancer Drug Research | Conditions: Prostatic Neoplasms | Phase 1, Phase 2 | Status: COMPLETED